Ely Benaim Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Ely Benaim.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Ely Benaim. Ely Benaim is Chief Medical Officer in REXAHN PHARMACEUTICALS, INC. ($RNN) and Chief Medical Officer in NovoCure Ltd ($NVCR).
Latest Insider Trading Transactions of Ely Benaim
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 14 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 180.48 | 1,943 | 350,673 | 29,054 | 31 K to 29.1 K (-6.27 %) |
Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 69.37 | 3,474 | 240,991 | 19,404 | |
Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 83.30 | 651 | 54,228 | 3,904 | |
Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 47.56 | 1,833 | 87,177 | 10,998 | |
Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 200.00 | 3,474 | 694,800 | 33,259 | 36.7 K to 33.3 K (-9.46 %) |
Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 69.37 | 3,474 | 240,991 | 36,733 | 33.3 K to 36.7 K (+10.45 %) |
Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 200.00 | 651 | 130,200 | 33,259 | 33.9 K to 33.3 K (-1.92 %) |
Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 83.30 | 651 | 54,228 | 33,910 | 33.3 K to 33.9 K (+1.96 %) |
Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 200.00 | 1,833 | 366,600 | 33,259 | 35.1 K to 33.3 K (-5.22 %) |
Apr 15 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 47.56 | 1,833 | 87,177 | 35,092 | 33.3 K to 35.1 K (+5.51 %) |
Mar 09 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 131.53 | 2,918 | 383,805 | 33,259 | 36.2 K to 33.3 K (-8.07 %) |
Mar 05 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 69.37 | 3,475 | 241,061 | 22,878 | |
Mar 05 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 137.55 | 1,888 | 259,702 | 36,177 | 38.1 K to 36.2 K (-4.96 %) |
Mar 05 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 150.78 | 3,475 | 523,961 | 38,065 | 41.5 K to 38.1 K (-8.37 %) |
Mar 05 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 69.37 | 3,475 | 241,061 | 41,540 | 38.1 K to 41.5 K (+9.13 %) |
Mar 04 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 153.09 | 16,003 | 2,449,899 | 16,003 | |
Mar 04 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Grant | A | 0.00 | 8,709 | 0 | 38,065 | 29.4 K to 38.1 K (+29.67 %) |
Dec 22 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 83.30 | 651 | 54,228 | 4,555 | |
Dec 22 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 47.56 | 1,833 | 87,177 | 12,831 | |
Dec 22 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 156.71 | 651 | 102,018 | 29,356 | 30 K to 29.4 K (-2.17 %) |
Dec 22 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 83.30 | 651 | 54,228 | 30,007 | 29.4 K to 30 K (+2.22 %) |
Dec 22 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 156.71 | 1,833 | 287,249 | 29,356 | 31.2 K to 29.4 K (-5.88 %) |
Dec 22 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 47.56 | 1,833 | 87,177 | 31,189 | 29.4 K to 31.2 K (+6.24 %) |
Aug 05 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 76.06 | 660 | 50,200 | 29,356 | 30 K to 29.4 K (-2.20 %) |
Aug 03 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 76.39 | 341 | 26,048 | 30,016 | 30.4 K to 30 K (-1.12 %) |
Aug 03 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Grant | A | 50.41 | 325 | 16,382 | 30,357 | 30 K to 30.4 K (+1.08 %) |
May 12 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 0.00 | 4,206 | 0 | 8,410 | |
May 12 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 63.73 | 1,611 | 102,666 | 15,211 | 16.8 K to 15.2 K (-9.58 %) |
May 12 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Buy | M | 63.84 | 4,206 | 268,511 | 16,822 | 12.6 K to 16.8 K (+33.34 %) |
Mar 05 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 69.37 | 27,794 | 1,928,070 | 27,794 | |
Mar 05 2020 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Grant | A | 0.00 | 14,415 | 0 | 30,032 | 15.6 K to 30 K (+92.30 %) |
Aug 01 2019 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 83.30 | 5,206 | 433,660 | 5,206 | |
Aug 01 2019 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Grant | A | 0.00 | 3,001 | 0 | 15,617 | 12.6 K to 15.6 K (+23.79 %) |
Mar 01 2019 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Option Exercise | M | 0.00 | 2,375 | 0 | 4,750 | |
Mar 01 2019 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Buy | M | 0.00 | 2,375 | 0 | 4,750 | 2.4 K to 4.8 K (+100.00 %) |
Jan 25 2019 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 0.62 | 100,000 | 62,100 | 100,000 | |
Mar 09 2018 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 1.78 | 200,000 | 356,000 | 200,000 | |
Jan 30 2018 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 2.29 | 45,443 | 104,064 | 45,443 | |
Jan 24 2017 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 0.00 | 95,000 | 0 | 95,000 | |
Jan 24 2017 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 0.18 | 450,000 | 82,800 | 450,000 | |
Feb 01 2016 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 0.35 | 500,000 | 175,000 | 500,000 | |
Feb 01 2016 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 0.35 | 98,734 | 34,557 | 98,734 | |
Feb 04 2015 | RNN | REXAHN PHARMACEUTI ... | Benaim Ely | Chief Medical Offic ... | Option Exercise | A | 0.71 | 1,200,000 | 852,000 | 1,200,000 |
Page: 1